[{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Multi-modular Engineered Treg Cell Therapy","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Quell Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Quell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Quell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"Jeito Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"QEL-001","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Quell Therapeutics","amount2":0.16,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.16,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Quell Therapeutics \/ Jeito Capital","highestDevelopmentStatusID":"5","companyTruncated":"Quell Therapeutics \/ Jeito Capital"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Treg-based Cell Therapy","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Quell Therapeutics","amount2":2.0899999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":2.0899999999999999,"dosageForm":"","sponsorNew":"Quell Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"Quell Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"QEL-001","moa":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Quell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Quell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Quell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"eXmoor pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"QEL-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Quell Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Quell Therapeutics \/ eXmoor pharma","highestDevelopmentStatusID":"14","companyTruncated":"Quell Therapeutics \/ eXmoor pharma"}]

Find Clinical Drug Pipeline Developments & Deals by Quell Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Quell & eXmoor are partnering on the process transfer, scale-up, and Phase 1/2 clinical manufacturing of multiple autologous CAR-Treg cell therapies, including QEL-001, for liver transplant patients.

                          Brand Name : QEL-001

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          September 24, 2024

                          Lead Product(s) : QEL-001

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : eXmoor pharma

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : QEL-001, its autologous engineered CAR-Treg cell therapy, which is being investigated in Phase 1/2 trial in patients with liver transplant patients.

                          Brand Name : QEL-001

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          June 04, 2024

                          Lead Product(s) : QEL-001

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The collaboration aims to focus on the type 1 diabetes and inflammatory bowel disease using Quell’s proprietary toolbox of Treg cell engineering modules, including its innovative Foxp3 Phenotype Lock, to develop autologous multi-modular Treg cell thera...

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : $85.0 million

                          June 09, 2023

                          Lead Product(s) : Treg-based Cell Therapy

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Undisclosed

                          Sponsor : AstraZeneca

                          Deal Size : $2,085.0 million

                          Deal Type : Collaboration

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Proceeds to be used to fund clinical development of QEL-001 in liver transplantation, to accelerate development of its product pipeline across transplantation, neuroinflammatory and autoimmune diseases, and enhance its multi-modular engineered Treg platf...

                          Brand Name : QEL-001

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          November 29, 2021

                          Lead Product(s) : QEL-001

                          Therapeutic Area : Immunology

                          Highest Development Status : IND Enabling

                          Sponsor : Jeito Capital

                          Deal Size : $156.0 million

                          Deal Type : Series B Financing

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Lead Product(s) : Multi-modular Engineered Treg Cell Therapy

                          Therapeutic Area : Immunology

                          Study Phase : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : The QEL-001 CAR is specific for HLA-A2, which localizes the activity of the CAR-Tregs to the site of the transplanted organ in HLA-A2 mismatch liver transplant patients (i.e. HLA-A2 negative recipients who received an HLA-A2 positive donor liver).

                          Brand Name : QEL-001

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          October 27, 2021

                          Lead Product(s) : Multi-modular Engineered Treg Cell Therapy

                          Therapeutic Area : Immunology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank